Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypes | Zendy

Pouya Hassandarvish | Zendy; Adrian Oo | Zendy; Amin Jokar | Zendy; Alexander Zukiwski | Zendy; Stefan Proniuk | Zendy; Sazaly Abu Bakar | Zendy; Keivan Zandi | Zendy

Open Access

Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypes

Author(s) -

Pouya Hassandarvish,

Adrian Oo,

Amin Jokar,

Alexander Zukiwski,

Stefan Proniuk,

Sazaly Abu Bakar,

Keivan Zandi

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx191

Subject(s) - dengue virus , in vitro , vero cell , virology , docking (animal) , biology , serotype , dengue fever , virus , medicine , biochemistry , nursing

With no clinically effective antiviral options available, infections and fatalities associated with dengue virus (DENV) have reached an alarming level worldwide. We have designed this study to evaluate the efficacy of the celecoxib derivative AR-12 against the in vitro replication of all four DENV serotypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research